This The Brookings Institution report shows it’s critical for lawmakers to focus attention on the real problem: Big Pharma’s list prices: brookings.edu/articles/a-bri…

Without PBMs, Big Pharma would be unchecked - forcing patients & taxpayers to pay high list prices. Current proposed legislation may have unintended negative consequences, according to The Brookings Institution: brookings.edu/articles/a-bri…

Drugmakers use the patent system to keep the price of GLP-1s high for patients. Keep reading: affordableprescriptiondrugs.org/big-pharmas-fi…

Drug manufacturers charge Americans thousands of dollars more for weight-loss drugs than prices abroad. It’s as straightforward as that. affordableprescriptiondrugs.org/big-pharmas-fi…

Year over year, Big Pharma raises the list price of GLP-1s and other brand drugs. In January alone, Novo Nordisk increased the price of Ozempic by 3.5%. Since 2017, its price has increased an astonishing 38%. More from CSRxP: csrxp.org/dose-of-realit…

PBMs negotiate discounts from drug manufacturers, generating savings for patients at the pharmacy counter, while Big Pharma stacks the deck against prices by keeping prices high. affordableprescriptiondrugs.org/big-pharmas-fi…

.@JCScottPCMA’s RealClearHealth op-ed explains why employers need and value flexibility when it comes to the design of their health care benefits.realclearhealth.com/blog/2024/06/1…

"As the only actor in the pharmaceutical supply chain actively working to lower out-of-pocket costs for patients, PBMs are crucial to offsetting Big Pharma’s out-of-control prices.” Read more in our blog: affordableprescriptiondrugs.org/big-pharmas-fi…

“Congress cannot risk leaving employers to fend for themselves against pharmaceutical giants or restrict flexibility, options and savings that help businesses design benefits that work best for their unique needs.” - @JCScottPCMA in RealClearHealth realclearhealth.com/blog/2024/06/1…

Study after study show: rebates negotiated by PBMs DO NOT increase drug costs. The truth: PBMs are a counterweight to Big Pharma’s anticompetitive tactics: affordableprescriptiondrugs.org/the-wall-stree…

.The Wall Street Journal asks: “If rebates are a problem, why does Congress require them for government insurance plans?” affordableprescriptiondrugs.org/the-wall-stree…

Evidence is piling up, refuting claims that rebates are to blame for high list prices of prescription drugs. affordableprescriptiondrugs.org/the-wall-stree…

NEW: The Wall Street Journal’s Editorial Board calls out fundamental flaws in recent claims about PBMs: affordableprescriptiondrugs.org/the-wall-stree…

PBMs are committed to improving access to popular weight-loss drugs and to keeping their costs low for consumers. affordableprescriptiondrugs.org/the-wall-stree…

.The Wall Street Journal’s Editorial Board sets the record straight about rebates: “net insulin prices after rebates have declined over time. This suggests competition fueled by the PBMs is working.” affordableprescriptiondrugs.org/the-wall-stree…

Simply put: “It’s time for lawmakers to hold Big Pharma accountable for the high price of prescription drugs and protecting the tools PBMs use to lower drug costs is crucial for employers and unions.” affordableprescriptiondrugs.org/the-wall-stree…

In a new Bloomberg Law article, Anthony LoSasso explains how PBMs play a crucial role in reducing drug costs for Americans. Weakening them could lead to higher prices and fewer options for patients. More: news.bloomberglaw.com/us-law-week/ph…

“Rather than dismantle mechanisms that counterbalance high drug costs, we should focus on enhancing market competition throughout the pharmaceutical supply chain.” - Anthony LoSasso in @Blaw: news.bloomberglaw.com/us-law-week/ph…

Legislation that weakens PBM practices like rebating only strengthens Big Pharma's bargaining power, writes Anthony LoSasso for Bloomberg Law:  news.bloomberglaw.com/us-law-week/ph…

"The stakes are high for affordable access to medications. Preserving PBMs' role in negotiating lower prices is essential for a healthcare system that prioritizes patients.” - Anthony LoSasso news.bloomberglaw.com/us-law-week/ph…